Annovis Bio to Present Comprehensive Buntanetap Data at Parkinson Study Group Meeting

Annovis Bio Inc. will present new data on its lead drug candidate buntanetap at the 2025 Annual Meeting of the Parkinson Study Group in San Diego. The presentation will expand on recent Phase 3 biomarker results showing that Parkinson's disease patients with amyloid co-pathology experience more severe cognitive decline, which is reversed by buntanetap treatment. The drug also reduces tau biomarkers linked to disease progression, providing a dual mechanism of action against key neurodegenerative pathways.

The company will debut a cross-study comparison of all completed clinical trials, offering the most comprehensive view to date of cognitive outcomes across different neurodegenerative indications. This analysis underscores that patients with amyloid pathology achieve the greatest cognitive benefit from buntanetap treatment, supporting the company's strategic development path forward. The findings have significant implications for treatment approaches in both Parkinson's and Alzheimer's diseases, where amyloid and tau pathology play central roles in disease progression.

The biomarker results showing reduction in tau levels alongside cognitive improvement in patients with amyloid co-pathology suggest buntanetap may address fundamental disease processes rather than just symptoms. This distinction is crucial in neurodegenerative disease treatment, where most current therapies provide only symptomatic relief without modifying disease progression. The cross-study comparison allows researchers to evaluate treatment effects across different patient populations and disease stages, providing valuable insights for future clinical trial design and patient selection strategies.

The upcoming presentation at the Parkinson Study Group meeting represents an opportunity for the scientific community to evaluate the latest data on buntanetap's potential to address cognitive decline in neurodegenerative diseases. The findings come at a critical time when the medical community seeks more effective treatments for Parkinson's and Alzheimer's diseases, both of which represent growing public health challenges as populations age worldwide. The company maintains detailed information about its research and development programs on its official website at https://www.annovisbio.com.

The comprehensive data analysis to be presented builds upon previous clinical findings and provides stronger evidence for buntanetap's mechanism of action in addressing multiple aspects of neurodegeneration. Annovis Bio's presentation at the prestigious Parkinson Study Group meeting represents an important milestone in the clinical development of buntanetap. Investors and researchers can access additional company information through the investor relations portal at https://ibn.fm/ANVS.